Orforglipron (Foundayo): The First GLP-1 Pill With No Food Rules
Foundayo (orforglipron) is an FDA-approved daily weight-loss pill and the first oral small-molecule GLP-1. Here is what it is, what the trials showed, and how it compares to what we offer.
What is orforglipron (Foundayo)?
Orforglipron, sold under the brand name Foundayo by Eli Lilly, is a once-daily oral GLP-1 medication for weight management. The FDA approved it on April 1, 2026. Its headline feature is convenience: it is a pill with no food, water, or timing restrictions, unlike the older oral semaglutide tablet that has strict fasting rules. One technical point matters for accuracy: orforglipron is a small molecule, not a peptide. That is what lets it work as a simple daily pill and be manufactured at large scale.
How does it work?
Like other GLP-1 medications, orforglipron activates the GLP-1 receptor, which reduces appetite and slows stomach emptying, helping people eat less and feel full sooner. The difference is the delivery: a small-molecule pill taken once a day rather than a weekly injection or a fasting-dependent tablet.
Ready to start?
$199 Skeptics’ Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialWhat did the trials show?
In the ATTAIN-1 program (about 3,127 adults without diabetes), orforglipron produced dose-dependent average weight loss of roughly 11 to 12% at 72 weeks. In Eli Lilly's April 2026 communications, the company described "an average of 27 pounds at the highest dose." Maintenance evidence comes from ATTAIN-MAINTAIN (Aronne LJ et al., Nature Medicine, 2026; PMID 42120723), which found orforglipron maintained roughly 74.7% to 79.3% of prior body-weight reduction at 52 weeks in people who switched from an injectable like tirzepatide or semaglutide. As with any medication, individual results vary.
Is Foundayo FDA-approved, and what does it cost?
Yes. Foundayo is FDA-approved and on the U.S. market. Per Lilly's April 1, 2026 release, it is available through LillyDirect with free home delivery, starting at $25 per month with commercial insurance coverage and $149 per month for self-pay at the lowest dose, with higher doses up to about $399 per month, and Medicare Part D as low as $50 per month beginning July 1, 2026. Prices change, so confirm current pricing with the manufacturer before relying on any figure.
How is Foundayo different from compounded semaglutide?
Foundayo is a brand-name, FDA-approved pill made by Eli Lilly. Compounded semaglutide and tirzepatide are prepared per prescription by licensed U.S. pharmacies and are not FDA-approved or brand-identical. They are different products with different regulatory status. New Hope Weight Loss does not dispense Foundayo and cannot compound a copy of an approved drug. What we provide is physician-supervised compounded semaglutide and tirzepatide, plus honest guidance if a branded oral option turns out to be the better fit for you.
What you can start today at New Hope Weight Loss
What a licensed clinic can legitimately offer right now is physician-supervised, compounded GLP-1 care. After a one-time $119 medical review with Dr. Sharma, eligible patients receive compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial if you want to test the waters first. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality. Care is delivered in person in Orange County and by telehealth across California and additional states.
Frequently asked questions
Is orforglipron (Foundayo) FDA-approved?
Yes. The FDA approved orforglipron, branded Foundayo, on April 1, 2026. It is the first once-daily small-molecule oral GLP-1 and is available through LillyDirect. It is not a peptide, which is part of why it can be taken as a simple daily pill without food or timing rules.
How much weight did people lose on orforglipron?
In the ATTAIN-1 program of adults without diabetes, orforglipron produced dose-dependent average loss of about 11 to 12% at 72 weeks, and Lilly described about 27 pounds at the highest dose. ATTAIN-MAINTAIN (PMID 42120723) found it maintained roughly 75 to 79% of earlier weight loss at 52 weeks after switching from an injectable. Individual results vary.
Can New Hope Weight Loss prescribe Foundayo?
We do not dispense Foundayo, and no clinic can compound a copy of an FDA-approved drug. What we offer is physician-supervised compounded semaglutide and tirzepatide, with honest guidance about all of your options. If a branded oral medication is the better fit, your physician will tell you.
Is the Foundayo pill better than a weekly injection?
Neither is universally 'better.' A daily pill is more convenient for some people; a weekly injection suits others. Trial average weight loss for orforglipron (about 11 to 12%) was generally lower than the highest injectable figures, but convenience, tolerability, cost, and your medical history all matter. A physician can help you choose.
What is the difference between Foundayo and compounded semaglutide?
Foundayo is a brand-name, FDA-approved pill. Compounded semaglutide is prepared per prescription by a licensed U.S. pharmacy and is not FDA-approved or brand-identical. They are different products with different regulatory status, which an honest clinic will explain rather than blur.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.